To print this article, all you need is to be registered or login on Mondaq.com.
Sunday, February 28, 2021, was Rare Disease Day. With so much
focus on COVID-19 throughout 2020, it s important to recognize
the continued work done in rare disease drug development by
sponsors and FDA throughout 2020. In addition, a number of policies
implemented in response to COVID-19 are expected to have a positive
impact on rare disease drug development going forward. Yet, the
lasting nature of these policies, post-pandemic, remains uncertain,
creating an opportunity for rare disease drug sponsors to be
proactive in engaging with regulatory authorities and the patient
To embed, copy and paste the code into your website or blog:
Sunday, February 28, 2021, was Rare Disease Day. With so much focus on COVID-19 throughout 2020, it’s important to recognize the continued work done in rare disease drug development by sponsors and FDA throughout 2020. In addition, a number of policies implemented in response to COVID-19 are expected to have a positive impact on rare disease drug development going forward. Yet, the lasting nature of these policies, post-pandemic, remains uncertain, creating an opportunity for rare disease drug sponsors to be proactive in engaging with regulatory authorities and the patient community to advocate the retention of these positive policy developments.